Literature DB >> 17690114

Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency.

Jyotsna Pandey1, Sarah M Umphress, Yang Kang, Jerry Angdisen, Alena Naumova, Kim L Mercer, Tyler Jacks, Sonia B Jakowlew.   

Abstract

Oncogenic K-ras is one of the most common genetic alterations in human lung adenocarcinomas. In addition, inactivation of clusters of tumor suppressor genes is required to bring about classical characteristics of cancer including angiogenesis as a prelude to invasion and metastasis. Transforming growth factor-beta (TGF-beta) 1 is a tumor suppressor gene that is implicated in lung cancer progression. Although in vitro studies have shown that TGF-beta1 and Ras pathways cooperate during tumorigenesis, the biology of interaction of TGF-beta1 and Ras has not been studied in in vivo tumorigenesis. We hypothesized that inactivation of TGF-beta1 in addition to oncogeneic activation of K-ras would lead to early initiation and faster progression to lung adenocarcinoma and invasion and metastasis. Heterozygous (HT) TGF-beta1 mice were mated with latent activatable (LA) mutated K-ras mice to generate TGF-beta1(+/+), K-ras LA (wild-type (WT)/LA) and TGF-beta1(+/-), K-ras LA (HT/LA) mice. Both HT/LA and WT/LA mice developed spontaneous lung tumors, but HT/LA mice progressed to adenocarcinomas significantly earlier compared with WT/LA mice. In addition, WT/LA adenocarcinomas had significantly higher angiogenic activity compared with HT/LA adenocarcinomas. Thus, while oncogenic K-ras mutation and insensitivity to the growth regulatory effects of TGF-beta1 is essential for initiation and progression of mouse lung tumors to adenocarcinoma, a full gene dosage of TGF-beta1 is required for tumor-induced angiogenesis and invasive potential. This study identifies a number of genes not previously associated with lung cancer that are involved in tumor induction and progression. In addition, we provide evidence that progression to invasive angiogenic lesions requires TGF-beta1 responsiveness in addition to Ras mutation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690114     DOI: 10.1093/carcin/bgm136

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Stephen P Malkoski; Sarah M Haeger; Timothy G Cleaver; Karen J Rodriguez; Howard Li; Shi-Long Lu; William J Feser; Anna E Barón; Daniel Merrick; Jessyka G Lighthall; Hideaki Ijichi; Wilbur Franklin; Xiao-Jing Wang
Journal:  Clin Cancer Res       Date:  2012-03-07       Impact factor: 12.531

2.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

3.  Interaction of tumor cells with the microenvironment.

Authors:  Hendrik Ungefroren; Susanne Sebens; Daniel Seidl; Hendrik Lehnert; Ralf Hass
Journal:  Cell Commun Signal       Date:  2011-09-13       Impact factor: 5.712

4.  Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity.

Authors:  Rodney B Luwor; Dulani Hakmana; Josephine Iaria; Thao V Nheu; Richard J Simpson; Hong-Jian Zhu
Journal:  Mol Cancer       Date:  2015-02-22       Impact factor: 27.401

Review 5.  Transforming growth factor-beta in breast cancer: too much, too late.

Authors:  Mary Helen Barcellos-Hoff; Rosemary J Akhurst
Journal:  Breast Cancer Res       Date:  2009-02-26       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.